

Patent Docket P1381R1C1P4C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Jian Chen et al. Serial No.: 10/617573 Filed: July 11, 2003 For: <i>IL-17 Homologous Polypeptides and Therapeutic Uses Thereof</i>	Group Art Unit: Unknown Examiner: Unknown Customer No.: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 8, 2003 <i>P. Tobin</i> Patty Tobin
---	--

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

1. Information Disclosure Statement (dup)
2. Form 1449 with Exhibits A1-A24 and B1-B33 Blast Results
3. Certificate of Mailing
6. Post card.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.


Respectfully submitted,

GENENTECH, INC.

Date: October 8, 2003

By:

Elizabeth M. Barnes
Elizabeth M. Barnes, Ph.D.
Reg. No. 35,059
Telephone No. (650) 225-4563



Patent Docket P1381R1C1P4C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Jian Chen et al. Serial No.: 10/617573 Filed: July 11, 2003 For: IL-17 Homologous Polypeptides and Therapeutic Uses Thereof	Group Art Unit: Unknown Examiner: Unknown Customer No.: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Arlington, VA 22313-1450 on October 8, 2003 <i>P. Tobin</i> Patty Tobin
---	---

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Arlington, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR § 1.97(c), and is accompanied by the fee set forth in 37 CFR § 1.17(p) **and** a statement as specified in 37 CFR § 1.97(e), as checked below.

[If either of boxes 37 CFR § 1.97(c) or 37 CFR § 1.97(d) is checked above, the following statement under 37 CFR § 1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR § 1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR § 1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR § 1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified). Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 10/000,157, filed October 30, 2001 and relied upon in this application for an earlier filing date under 35 USC § 120.

☒ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "Exhibit A BLAST Results A-1- A-24" (nucleotide) and "Exhibit B BLAST Results B-1 - B-33)" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of

the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR § 1.17(p).

Respectfully submitted,

GENENTECH, INC.

By:



Elizabeth M. Barnes, Ph.D.

Reg. No. 35,059

Telephone No. (650) 225-4563

Date: October 8, 2003

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1381R1C1P4C1

Serial No.

10/617573

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Jian Chen et al.

Filing Date

11 Jul 2003

Group

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
* 1	5,536,637	16.07.96	Jacobs, K.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
* 2	WO00/53752						
* 3	WO00/70050						
* 4	WO00/73452						
* 5	WO96/29408						
* 6	WO99/14240						
* 7	WO99/46281						
* 8	WO99/60127						
* 9	WO 94/01548		PCT				
*10	WO 98/49310	05.11.98	PCT				
*11	WO 99/03982	28.01.99	PCT				
*12	WO 99/32632	01.07.99	PCT				
*13	WO 99/35267	15.07.99	PCT				
*14	WO 99/61617	12.02.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*15	Aarvak et al., "IL-17 Is Produced by Some Proinflammatory Th1/Th0 Cells but not by Th2 Cells" <u>Journal of Immunology</u> 162:1246-1251 (1999)
*16	Albanesi et al., "IL-17 Is Produced by Nickel-Specific T Lymphocytes and Regulates ICAM-1 Expression and Chemokine Production in Human Keratinocytes: Synergistic or Antagonist Effects with IFN- γ and TNF- α " <u>Journal of Immunology</u> 162:494-502 (1999)
*17	Aliprantis, "Cell Activation and Apoptosis by Bacterial Lipoproteins Through Toll-like Receptor-2" <u>Science</u> 285:736-739 (Jul 30, 1999)
*18	Altschul and Gish, "Local Alignment Statistics" <u>Methods in Enzymology</u> 266:460-480 (1996)
*19	Amin and Abramson., "The Role of Nitric Oxide in Articular Cartilage Breakdown in Osteoarthritis." <u>Curr. Opin. Rheum.</u> 10(3):263-268 (1998)
*20	Antonyasamy et al., "Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors" <u>J. Immunol.</u> 162(1):577-584 (1999)
*21	Antonyasamy, M.A. et al., "Evidence for a role of IL-17 in alloimmunity: a novel IL-17 antagonist promotes heart graft survival" <u>Transplant Proc.</u> 31(1-2):93 (1999)
*22	Arend et al., "Cytokines and Cytokine Inhibitors or Antagonists in Rheumatoid Arthritis" <u>Arthritis Rheum.</u> 33:305-315 (1990)
*23	Attur et al., "Interleukin-17 Up-Regulation of Nitric Oxide Production in Human Osteoarthritis Cartilage" <u>Arthritis and Rheumatism</u> 40(6):1050-1053 (Jun 1997)
*24	Awane et al., "NF- κ B-Inducing Kinase is a Common Mediator of IL-17-TNF- α , and IL-1 β -Induced Chemokine Promoter Activation in Intestinal Epithelial Cells" <u>J. Immunol</u> 162:5337-5344 (1999)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1381R1C1P4C1Serial No.
10/617573

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Jian Chen et al.Filing Date
11 Jul 2003

Group

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*25	Biesinger et al., "Stable growth transformation of human T lymphocytes by Herpesvirus saimiri" <u>Proc. Natl. Acad. Sci. USA</u> 89:3116-3119 (Apr 1992)
*26	BLAST Results A-1 - A-1 (Dayhoff)
*27	BLAST Results B-1 - B-10 (Dayhoff)
28	Blast Results, "A1-A24" <u>Exhibit A</u>
29	Blast Results, "B1-B33" <u>Exhibit B</u>
*30	Brightbill, "Host Defense Mechanisms Triggered by Microbial Lipoproteins Through Toll-Like Receptors" <u>Science</u> 285:732-736 (Jul 30, 1999)
*31	Broxmeyer, H.E., "Is Interleukin 17, An Inducible Cytokine That Stimulates Production of Other Cytokines, Merely a Redundant Player in a Sea of Other Biomolecules?" <u>Journal of Experimental Medicine</u> 183:2411-2415 (Jun 1996)
*32	Chabaud et al., "Enhancing Effect of IL-17 on IL-1-Induced IL-6 and Leukemia Inhibitory Factor Production by Rheumatoid Arthritis Synoviocytes and Its Regulation by Th2 Cytokines" <u>Journal of Immunology</u> 161:409-414 (1998)
*33	Chabaud et al., "Human Interleukin-17: A T Cell-Derived Proinflammatory Cytokine Produced by the Rheumatoid Synovium" <u>Arthritis & Rheumatism</u> 42(5):963-970 (1999)
*34	Faerman, "The expression of the regulatory myosin light chain 2 gene during mouse embryogenesis" <u>Development</u> 118:919-929 (1993)
*35	Farndale et al., "Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue" <u>Biochem. Biophys. Acta</u> 883:173-177 (1986)
*36	Fleckenstein and Desrosiers, "Herpesvirus saimiri and herpesvirus ateles" <u>In the Herpesviruses</u> , I.B. Roizman, ed., NY:Plenum Publishing Press pps. 253-332 (1982)
*37	Fossiez et al., "Interleukin-17" <u>Int. Rev. Immunol.</u> 16(5-6):541-551 (1998)
*38	Fossiez et al., "T Cell Interleukin-17 Induces Stromal Cells to Produce Proinflammatory and Hematopoietic Cytokines" <u>Journal of Experimental Medicine</u> 183(6):2593-2603 (Jun 1996)
*39	Gordon et al., "Molecular immunobiology of macrophages: recent progress" <u>Current Opinion in Immunology</u> 7:24-33 (1995)
*40	Guo, "Biochemical Characterization of Endogenously Formed Eosinophilic Crystals in the Lungs of Mice" <u>The Journal of Biological Chemistry</u> 275(11):8032-8037 (Mar 17, 2000)
*41	Hillier et al., "af37c02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 1033826 3'" (Accession number AA780147) (Feb 6, 1998)
*42	Hillier et al., "zf01f09.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 375689 3'" (Accession number AA033733) (Feb 4, 1997)
*43	Infante-Duarte, "Microbial Lipopeptides Induce the production of IL-17 in Th cells" <u>The Journal of Immunology</u> 165:6107-6115 (2000)
*44	Jovanovic et al., "IL-17 Stimulates the Production and Expression of Proinflammatory Cytokines, IL- β and TNF- α , by Human Macrophages" <u>J. Immunol</u> 160:3513-3521 (1998)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1381R1C1P4C1

Serial No.

10/617573

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)



Applicant

Jian Chen et al.

Filing Date

11 Jul 2003

Group

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*45	Jovanovic et al., "Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages" <u>Arthritis and Rheumatism</u> 43(5):1134-1144 (2000)
*46	Kennedy et al., "Mouse IL-17: A Cytokine Preferentially Expressed by $\alpha\beta$ TCR+CD4-CD8- T Cells" <u>Journal of Interferon and Cytokine Research</u> 16(8):611-617 (1996)
*47	Kingsley et al., "Joint destruction in rheumatoid arthritis: biological bases" <u>Clin. Exp. Rheumatol.</u> 15:S3-S14 (1997)
*48	Klein et al., "Selection for Genes Encoding Secreted Proteins and Receptors" <u>Proc. Natl. Acad. Sci. USA</u> 93(14):7108-7113 (1996)
*49	Kong et al., "Activated T Cells Regulate Bone Loss and Joint Destruction in Adjuvant Arthritis through Osteoprotegerin Ligand" <u>Nature</u> 402(6759):304-309 (1999)
*50	Kotake et al., "IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis" <u>Journal of Clinical Investigation</u> 103(9):1345-1352 (1999)
*51	Laan, "Neutrophil Recruitment by Human IL-17 via C-X-C- Chemokine release in the Airways" <u>The Journal of Immunology</u> 162:2347-2352 (1999)
*52	Lee, et al., "IL-17E, a Novel Proinflammatory Ligand for the IL-17 Receptor Homolog IL-17Rh1" <u>The Journal of Biological Chemistry</u> 276(2):1660-1664 (2001)
*53	Lennon et al., "The I.M.A.G.E. Consortium: An Integrated Molecular Analysis of Genomes and Their Expression" <u>Genomics</u> (Article #0177) 33:151-152 (1996)
*54	Li et al., "Cloning and characterization of the IL-17B and IL-17C two new members of the IL-17 cytokine family" <u>Proc. Natl. Acad. Sci. USA</u> 97(2):773-778 (2000)
*55	Linden, "Airway neutrophils and interleukin-17" <u>Eur Respir J</u> 15:973-977 (2000)
*56	Lotz et al., "IL-17 Promotes Cartilage Degradation" <u>Cytokines</u> (ACR Abstract Session 10, October 19, 1996, abstract #559) pps. S120 (1996)
*57	Lubberts, "IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion" <u>The Journal of Clinical Investigation</u> 105:1697-1710 (2000)
*58	Luckow et al., "Trends in the Development of Baculovirus Expression Vectors" <u>Bio/Technology</u> 6:47-55 (1988)
*59	March et al., "Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs" <u>Nature</u> 315:641-647 (Jun 20, 1985)
*60	Marra et al., "The WashU-HHMI Mouse EST project, Locus AA763404, 1/27/98, Accessed 12/13/00"
*61	Martel-Pelletier et al., "Major Signaling Pathways Involved in the IL-17 Induced Nitric Oxide (NO) Production in Human Osteoarthritic Chondrocytes" <u>Orthopaedic Research Society</u> (45th Annual Meeting, Feb 1-4, 1999, pt 2) 24:595 (1999)
*62	Matusiewicz et al., "Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis" <u>Multiple Sclerosis</u> 5:101-104 (1999)
*63	Metcalf, "Control of Granulocytes and Macrophages: Molecular, Cellular, and Clinical Aspects" <u>Science</u> 254:529-533 (Oct 25, 1991)
*64	Rouvier et al., "CTLA-8, Cloned from an Activated T Cell, Bearing AU-Rich Messenger RNA Instability Sequences, and Homologous to a Herpesvirus Saimiri Gene" <u>Journal of Immunology</u> 150(12):5445-5456 (Jun 15, 1993)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1381R1C1P4C1

Serial No.

10/617573

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Jian Chen et al.

Filing Date

11 Jul 2003

Group

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

*65	Schwarzenberger et al., "IL-17 Stimulates Granulopoiesis in Mice: Use of an Alternate, Novel Gene Therapy-Derived Method for In Vivo Evaluation of Cytokines" <u>Journal of Immunology</u> 161:6383-6389 (1998)
*66	Schwarzenberger, "Requirement of Endogenous Stem Cell Factor and granulocyte-Colony-Stimulating Factor for IL-17 Mediated Granulopoiesis" <u>The Journal of Immunology</u> 164:4783-4789 (2000)
*67	Seow, H.F., "Pathogen interactions with cytokines and host defence: an overview" <u>Vet Immunol. Immunopathol.</u> 63(1-2):139-148 (1998)
*68	Shalom-Barak et al., "Interleukin-17-induced Gene Expression in Articular Chondrocytes is Associated with Activation of Mitogen-activated Protein Kinases and NF- κ B" <u>Journal of Biological Chemistry</u> 273(42):27467-27473 (Oct 16, 1998)
*69	Shani, "Expression of the Rat Myosin Light-Chain 2 Gene in Transgenic Mice: Stage Specificity, Developmental Regulation, and Interrelation with the Endogenous Gene" <u>Molecular & Cellular Biology</u> 8(2):1006-1009 (Feb 1988)
*70	Shi, "A Novel Cytokine Receptor-Ligand Pair: Identification, Molecular Characterization and In Vivo Immunomodulatory Activity." <u>J. Biological Chemistry, American Society of Biological Chemists</u> , Baltimore 275(25):19167-19176 (Jun 23, 2000)
*71	Spriggs, M.K., "Interleukin-17 and Its Receptor" <u>Journal of Clinical Immunology</u> 17(5):366-369 (1997)
*72	Subramaniam et al., "Evidence for the Involvement of JAK/STAT Pathway in the Signaling Mechanism of Interleukin-17" <u>Biochem. & Biophys. Res. Comm.</u> 262:14-19 (1999)
*73	Subramaniam et al., "Interleukin-17 Induces Rapid Tyrosine Phosphorylation and Activation of Raf-1 Kinase in Human Monocytic Progenitor Cell Line U937" <u>Biochem. & Biophys. Res. Comm.</u> 259:172-177 (1999)
*74	Tartour et al., "Interleukin 17, a T-cell-derived Cytokine, Promotes Tumorigenicity of Human Cervical Tumors in Nude Mice" <u>Cancer Research</u> 59:3698-704 (1999)
*75	Teunissen et al., "Interleukin-17 and Interferon- γ Synergize in the Enhancement of Proinflammatory Cytokine Production by Human Keratinocytes" <u>J. Invest. Dermatol.</u> 111:645-649 (1998)
*76	Tian, "EVI27 encodes a novel membrane protein with homology to the IL-17 receptor" <u>Oncogene</u> 19:2098-2109 (2000)
*77	Van Bezooijen et al., "Interleukin-17: A New Bone Acting Cytokine In Vitro" <u>Journal of Bone and Mineral Research</u> 14(9):1513-1521 (1999)
*78	Van Kooten et al., "Interleukin-17 Activates Human Renal Epithelial Cells in Vitro and is Expressed during Renal Allograft Rejection" <u>J. Am. Soc. Nephrol.</u> 9:1526-1534 (1998)
*79	Vukicevic et al., "Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7)" <u>Proc. Natl. Acad. Sci.</u> 93:9021-9026 (1996)
*80	Witowski, "IL-17 Stimulates Intraperitoneal Neutrophil Infiltration Through the Release of GRO/141 Chemokine from Mesothelial Cells" <u>The Journal of Immunology</u> 165:5814-5821 (2000)
*81	Yao et al., "Herpesvirus Saimiri Encodes a New Cytokine, IL-17, which Binds to a Novel Cytokine Receptor" <u>Immunity</u> 3:811-821 (Dec 1995)
*82	Yao et al., "Human IL-17: A Novel Cytokine Derived from T Cells" <u>Journal of Immunology</u> 155(12):5483-5486 (1995)
*83	Yao et al., "Molecular Characterization of the Human Interleukin (IL)-17 Receptor" <u>Cytokine</u> 9(11):794-800 (Nov 1997)
*84	Zhu, "Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production" <u>J. Clin. Invest</u> 103(6):779-788 (Mar 1999)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1381R1C1P4C1

Serial No.

10/617573

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Jian Chen et al.

Filing Date

11 Jul 2003

Group	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.